4893 items matching your search terms.

Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study

Sullivan, D. Forder, P. Simes, J. Whiting, M. Kritharides, L. Merrifield, A. Donoghoe, M. Colman, P. G. Graham, N. Haapamäki, H. Keech, A.
DIABETES RESEARCH AND CLINICAL PRACTICE, 2011     DOI:10.1016/j.diabres.2011.07.028

Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 patients with type 2 diabetes in the FIELD study

Sullivan, D; Forder, P; Simes, J; Whiting, M; Kritharides, L; Merrifield, A; Donoghoe, M; Colman, PG; Graham, N; Haapamäki, H; Keech, A; for the FIELD Study Investigators,
DIABETES RESEARCH AND CLINICAL PRACTICE, 2011     DOI:10.1016/j.diabres.2011.07.028

Accuracy of the MeSH term ‘breast neoplasms’: ten years on

Tai, FM Willson, ML Ghersi, D

Early closure of neonatal oxygen targeting trials after higher survival in high target groups

Tarnow-Mordi, W Askie, L Hague, W Donoghoe, M Kirby, A Gebski, V Simes, J Davis, P Morley, C Doyle, L Darlow, B Brocklehurst, P Juszczak, E Stenson, B

Treatment of suspected or proven neonatal sepsis with human intravenous immunoglobulin: results of the International Neonatal Immunotherapy Study (INIS)

Tarnow-Mordi, W Darlow, B Brocklehurst, P for the INIS Trial Collaborative Group,

Improved targeting after software update in the BOOST II RCT of neonatal oxygen targeting

Tarnow-Mordi, W Donoghoe, M Ghadge, A Doyle, L Morley, C Davis, P Darlow, B for the BOOST II Trial Collaborative Group,

Risk of brain damage in babies from naphthalene in mothballs: call to consider a national ban [letter]

Tarnow-Mordi, WO Evans, NJ Lui, K Darlow, B Advisory Committee of the Australian and New Zealand Neonatal Network,

Need for larger trials in pediatric critical care and neonatal medicine [letter]

Tarnow-Mordi, W Kumar, P Kler, N
ACTA PAEDIATRICA, 2011     DOI:10.1111/j.1651-2227.2011.02251.x

Neonatal trials need thousands, not hundreds, to change global practice [letter]

Tarnow-Mordi, W Kumar, P Kler, N
ACTA PAEDIATRICA, 2011     DOI:10.1111/j.1651-2227.2011.02141.x

Necrotizing enterocolitis [letter]

Tarnow-Mordi, WO Wilkinson, D Trivedi, A

Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab

Tebbutt, NC; Murphy, F; Zannino, D; Wilson, K; Cummins, MM; Abdi, E; Strickland, AH; Lowenthal, RM; Marx, G; Karapetis, C; Shannon, J; Goldstein, D; Nayagam, SS; Blum, R; Chantrill, L; Simes, RJ; Price, TJ; on behalf of the Australasian Gastro-Intestinal Trials Group,
ANNALS OF ONCOLOGY, 2011     DOI:10.1093/annonc/mdq702

Quantification of typical, best-case and worst-case scenarios for metastatic breast cancer patients undergoing first line chemotherapy in south west sydney: a multicentre retrospective cohort analysis

Thientosapol, ES Tran, TT Adams, DH Della-Fiorentina, SA Chantrill, LA Kiely, BE

Phase 2 trial of aprepitant on days 1 to 7 for patients with germ cell tumors having cisplatin on days 1 to 5

Thomson, D Grimison, P Chatfield, M Stockler, M Toner, G Gebski, V Boland, A McDonald, A Olver, I

Phase 2 trial of aprepitant on days 1 to 7 for patients with germ cell tumors having cisplatin on days 1 to 5

Thomson, D Grimison, P Chatfield, M Stockler, M Toner, G Gebski, V Harrup, R Boland, A McDonald, A Olver, I

Phase II trial of aprepitant on days 1 to 7 for patients with germ cell tumors having cisplatin on days 1 to 5

Thomson, DB Grimison, PS Chatfield, MD Stockler, MR Toner, GC Gebski, V Harrup, RA Underhill, C Kichenadasse, G Singhal, N Boland, AL McDonald, A Olver, IN Australian and New Zealand Urogenital and Prostate Cancer Trials Group,